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Abstract
Adenosine, prostaglandin E2, or increased intracellular cyclic AMP concentration each elicit potent anti-inflammatory events
in human neutrophils by inhibiting functions such as phagocytosis, superoxide production, adhesion and cytokine release.
However, the endogenous molecular pathways mediating these actions are poorly understood. In the present study, we
examined their impact on the gene expression profile of stimulated neutrophils. Purified blood neutrophils from healthy
donors were stimulated with a cocktail of inflammatory agonists in the presence of at least one of the following anti-
inflammatory agents: adenosine A2A receptor agonist CGS 21680, prostaglandin E2, cyclic-AMP-elevating compounds
forskolin and RO 20-1724. Total RNA was analyzed using gene chips and real-time PCR. Genes encoding transcription
factors, enzymes and regulatory proteins, as well as secreted cytokines/chemokines showed differential expression. We
identified 15 genes for which the anti-inflammatory agents altered mRNA levels. The agents affected the expression profile
in remarkably similar fashion, suggesting a central mechanism limiting cell activation. We have identified a set of genes that
may be part of important resolution pathways that interfere with cell activation. Identification of these pathways will
improve understanding of the capacity of tissues to terminate inflammatory responses and contribute to the development
of therapeutic strategies based on endogenous resolution.
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Introduction
Neutrophils constitute the majority of circulating leukocytes and
are often the first cells to migrate toward inflammatory lesions,
where they exert host defense functions including the phagocytosis
of cell debris and invading microorganisms, the generation of
oxygen-derived reactive agents and the release of proteolytic
enzymes [1]. In response to specific stimuli, neutrophils can
synthesize and release an array of factors such as anti-microbial
proteins and extracellular matrix proteins as well as several
cytokines and chemokines and thereby play a major role in
orchestrating early stages of the inflammatory response [2].
Although recurrent infections in patients with defective neutrophil
function confirm their importance in host defense, these cells also
bear enormous destructive capacity and can elicit significant tissue
damage. Unchecked activation of neutrophils is associated with
pathological states such as ischemia, sepsis, chronic obstructive
pulmonary disease and rheumatoid arthritis [3–5]. It is therefore
of both fundamental and clinical interest to gain understanding of
not only the mechanisms that promote neutrophil functions, but
also of those that can restrict such activation and bring about the
resolution of inflammation.
Adenosine, through activation of the A2A receptor (A2AR) subtype,
ranks among the most potent agents limiting the inflammatory
activities of neutrophils. One of the first reports on this matter,
published more than two decades ago by Cronstein et al. [6],
determined that the autacoid inhibited superoxide production
resulting from inflammatory stimuli. Interest in adenosine and its
receptors has since fuelled major research efforts, which have
contributed to increased appreciation of their pivotal importance in
limiting inflammation [7–9]. High concentrations of extracellular
adenosine can be found in vivo in traumatized tissues and this
autacoid may have a role in reducing the accumulation of leukocytes
at the site of injury [10]. A paramount role for the A2AR subtype in
mediating anti-inflammatory activities has been for all practical
purposes established in previous studies [11–16]. The cyclic-AMP-
elevating Gs-protein-coupled A2AR subtype modulates key pro-
inflammatory neutrophil functions such as superoxide generation, de-
granulation and adhesion (reviewed in [17]). Endogenous adenosine
and A2AR agonists have shown to be potent inhibitors of leukotriene
and platelet-activating factor synthesis [13,18–20] and in contrast, to
stimulate COX-2 expression in neutrophils [21,22], thus increasing
the capacity of these cells to produce prostaglandin E2. This shift in
the profile of lipid mediator production from leukotrienes to
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phil-elicited inflammatory events. Recently, our laboratory reported
that A2AR activation had a striking inhibitory impact on the in vitro
and in vivo generation of tumor necrosis factor a and several other
neutrophil-derived cytokines and chemokines [23], confirming a
preeminent role for adenosine in restricting neutrophil activation.
Most of the anti-inflammatory activities of this autacoid through
A2AR engagement are thought to involve a rise in intracellular cyclic
AMP concentration [22,24,25]. Prostaglandin E2, acting through its
own set of receptors, is also a potent inhibitor of neutrophil
inflammatory functions and can, similarly to adenosine, modulate
pivotal neutrophil effector functions such as chemotaxis, aggregation,
superoxide production, lysozyme release and leukotriene B4
production by raising intracellular cyclic AMP concentration above
basal levels [22,26–33]. Adenosine and prostaglandin E2 thus clearly
stand out as two major anti-inflammatory signals, while elevated
intracellular cyclic AMP concentration, which can be pharmacolog-
ically achieved with a combination of the adenylate cyclase activator
forskolin and of the phosphodiesterase IV inhibitor RO-20-1724,
often appears to accompany their actions. However, the gene
activities that control inflammation resolution pathways remain
poorly understood.
In the present study, we used DNA microarray technology and
real-time PCR to examine the impact of major anti-inflammatory
signals, namely A2AR activation, prostaglandin E2 and elevated
intracellular cyclic AMP, on the gene expression profile of human
neutrophils stimulated by known inflammatory agonists. We have
identified a group of genes for which mRNA levels were
significantly altered by anti-inflammatory signals. This may
indicate their involvement in pivotal molecular signaling pathways
associated with the resolution of inflammation.
Results
Gene expression in stimulated human neutrophils
Microarray data is conform to the MIAME guidelines;
unsupervised, raw data was deposited in the GEO database
(geo@ncbi.nlm.nih.gov), submission number: GSE14465. Initial
analysis of the DNA microarray chips using the Affymetrix software
indicated that approximately 15,000 of the 54,675 sequences
recognized in the array (i.e. 27.5%) are expressed by resting human
neutrophils. Comparison between resting and neutrophils stimulat-
ed with a mixture ofpro-inflammatoryagonistsfor30 min,revealed
1,152 differentially expressedsequences,ofwhich401 corresponded
to known proteins [34] and are listed in Supplementary Table S1 in
descendingorderoftheexpressiondifferentialmagnitude.Usingthe
Kegg pathway database, we selected genes for further examination,
based on their potential implication in immune response processes
(http://www.genome.jp/kegg/pathway.html). Selected pathways
included: cytokine-cytokine receptor interaction, leukocyte trans-
endothelial migration, Jak-STAT signaling pathways, MAPK
signaling pathways, natural killer cell-mediated cytotoxicity,
apoptosis, Toll-like receptor signaling pathways, T & B cell receptor
signaling pathways, arachidonic acid metabolism, insulin signaling
pathways, neuroactive ligand-receptor interactions, focal adhesion,
ubiquitin-mediated protein lysis, and chronic myeloid leukemia. By
this approach, 68 genes were selected and essentially corresponded
to transcription factors, enzymes, regulatory elements, cytokines/
chemokines and receptors (Supplementary Table S2).
We sought to validate the gene chip results using real-time PCR
for analysis of the selected genes. This analysis corroborated a
significant differential expression between resting and stimulated
cells for 64 of the 68 genes. Integrated real-time PCR results are
presented in Figure 1. Overall, these results provided strong
corroboration of the gene chip assays, in terms of both the
identification of differentially expressed genes and the magnitude
of the differential expression. The majority of these genes were up-
regulated in stimulated cells, with increases reaching 800-fold in
some cases. Among these are members of the early growth
response family of transcription factors, the IL-1 receptor-like 1,
and cytokines/chemokines IL-1a/b, CXCL8 (IL-8), CCL20/23
and CXCL2/3, as well as suppressor of cytokine signaling (SOCS)
3. Other up-regulated genes encode for a number of acute phase
proteins such as IER2, 3 and 5, receptors GPR84 and ICAM1, as
well as for enzymes such as dual-specificity phosphatases (DUSP)
1, 2 and 5. In comparison, only a small number of genes were
Figure 1. Change in levels of mRNA expression by 64 genes in human neutrophils due to stimulation with inflammatory agonists.
Cells were stimulated as described in Materials and Methods for 30 min at 37uC. Values are ratios of mRNA levels (stimulated cells/un-stimulated cells)
as determined by real-time PCR, averaged6SEM for six independent experiments performed under identical conditions with a different single donor
of cells. *Selected MIP-2 primers do not discriminate between the highly homologous alpha and beta isoforms.
doi:10.1371/journal.pone.0004902.g001
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decreases were of relatively modest magnitude. This constitutes,
to our knowledge, a first comprehensive gene expression profiling
for inflammatory neutrophils.
Genes modulated by anti-inflammatory agents
We used the A2AR agonist CGS 21680, PGE2, or the cAMP-
elevating compounds RO 20-1724 (phosphodiesterase IV inhib-
itor) and forskolin (adenylate cyclase activator), which are potent
anti-inflammatory agents known to modulate neutrophil activation
[17], in order to determine their impact of the gene expression
profile of stimulated neutrophils. Analysis by gene chips revealed
that, of the 64 genes differentially expressed in stimulated cells, 28
appeared influenced by at least one of these agents (Supplemen-
tary Table S3). Several genes behaved as predicted; the inducible
cyclooxygenase COX-2 being up-regulated, while TNF-a and
MIP-1a down-regulated by A2AR activation, which is in line with
earlier findings [21,23]. These gene chip results were then
confronted with real-time PCR experiments performed with new
samples from six different donors, which confirmed significant
differential expression for 15 of the 28 genes (Figure 2). A2AR
engagement, PGE2 or cAMP-elevating agents each increased
mRNA expression of immunomodulatory transcription factors
NR4A3, ATF3, TNFAIP3 and IER2, of the enzyme COX-2, of
dual-specificity phosphatases 1 and 2 and of the regulatory
element SOCS3. Conversely, a number of genes were down-
regulated by the anti-inflammatory treatments, notably the pro-
inflammatory cytokines, TNF-a, macrophage inflammatory pep-
tide-1a (CCL3/MIP-1a), endothelin-1, members of the early-
growth response family of transcription factors (EGR2, EGR3)
and the DUSP5 enzyme (Supplementary Table S4). Remarkably,
the three distinct anti-inflammatory approaches each had a
comparable overall impact on the gene expression profile.
Gene chips and real-time PCR showed similar effects of PGE2
or pharmacological elevation of intracellular cAMP on most of the
genes affected by A2AR engagement, suggesting that even when
distinct receptors are engaged, signaling pathways eventually
merge and cAMP-dependent processes take part in a central anti-
inflammatory response. In order to address this point specifically,
we next stimulated neutrophils in the simultaneous presence of all
three types of anti-inflammatory agent. Messenger RNA levels of
the 15 genes identified earlier were determined by real-time PCR.
This experiment produced essentially the same result as obtained
with each anti-inflammatory strategy alone (Figure 3), further
advocating for an important role of these genes in limiting cell
activation. Indeed, no additive or synergistic effect was obtained
for the majority of the genes. The exceptions were NR4A3 and
DUSP5, for which the simultaneous presence of the anti-
inflammatory agents proved more potent than any individual
agent. Overall, these results support the concept of a relative
redundancy between the distinct anti-inflammatory agents and
more specifically their participation in a central and largely cAMP-
dependent cellular immunomodulatory response.
Time-course experiments were undertaken in which cells were
stimulated for periods of time ranging from 5 min to 4 h, alone or
in presence of the A2AR agonist CGS 21680. Messenger RNA
levels for genes of interest were measured by real-time PCR and
samples stimulated in the absence or presence of CGS 21680 were
compared in a time-matched manner. Depending on the gene,
A2AR activation elicited transient (,2 h) or sustained ($4h )
responses, indicative of gene-specific regulatory processes
(Figure 4). However, the impact on gene expression was typically
rapid, in most cases becoming apparent in less than 30 minutes.
Discussion
The scope of this work encompasses the development of novel
therapeutic strategies based on enabling endogenous anti-inflam-
matory pathways in the treatment of inflammatory conditions such
as rheumatoid arthritis, in which unchecked activation of cells can
cause significant tissue damage. By profiling gene expression in
stimulated neutrophils, we delineated a group of genes that
respond to immunomodulatory signals. Gene identification was
achieved using a gene chip approach and was corroborated by
real-time PCR. In response to three distinct anti-inflammatory
approaches, stimulated neutrophils shifted their expression of
specific genes. Cells responded to these different anti-inflammatory
signals in a strikingly similar fashion, which suggests the
engagement of a central endogenous system responsible for
uncoupling selected neutrophil inflammatory functions.
The pro-inflammatory, receptor-activating agonists Escherichia
coli lipopolysaccharide, granulocyte-macrophage colony-stimulat-
ing factor, tumor-necrosis factor a, formyl-methionyl-leucyl-
phenylalanine and interleukin 1b were chosen for their impor-
tance in inflammatory processes and for their well-documented
stimulatory effects on neutrophils [21–23,35–37]. In the course of
an inflammatory response, it is assumed that recruited neutrophils
are more likely to encounter a multitude of extracellular
messengers, rather than a single one. Even so, most studies of
anti-inflammatory agents have used a single agonist and for that
matter, a single anti-inflammatory agent, thereby locking down
data interpretation on pathways solicited by that particular agonist
only. In this study, we elected to stimulate neutrophils concur-
rently with a group of agonists chosen for their well-described
ability to engage distinct classes of receptors in neutrophils. GM-
CSF interacts with a receptor comprising tyrosine kinase activity
[38], fMLP signals through seven-transmembrane domain recep-
tors FPR1 and FPRL1 linked to heterotrimeric GTP-binding
proteins [39], LPS associates with LPS-binding proteins, then with
the Toll-Like receptor 4 and CD14 molecule [40], TNF-a binds to
its ceramide-linked receptors TNFRSF1A/TNFR1 and
TNFRSF1B/TNFBR [41] and finally, IL-1b engages its own
family of receptors (IL-1R1, IL-1R2, IL1-RL1) in the immuno-
globulin domain superfamily [42]. This multilateral stimulation,
likely closer to what inflammatory cells face, favorably elicits a
robust and more comprehensive cellular involvement, a suitable
situation for the study of anti-inflammatory processes.
The impact of the anti-inflammatory agents on cell response
was clearly multi-pronged, even considering only their effects on
gene expression. Genes involved encode transcription factors,
enzymes and regulatory factors, receptors and cytokines. It is of
interest that some of the genes were actually up-regulated by the
anti-inflammatory agents, implying an active cellular reaction
rather than a mere response to inhibition. Such up-regulated genes
included pivotal transcription factors that have been reported to
modulate numerous cell functions. For example, TNFAIP3
displays potent anti-inflammatory properties in a number of
different cell types, through the inhibition of NF-kB activation and
prevention of TLR-mediated responses [43–48]. ATF3 plays a
protective role in ischemia-reperfusion injury and in response to
stress [49,50]. NR4A3 prevents NF-kB activation, thereby
reducing inflammatory responses such as the generation of pro-
inflammatory cytokines. Available evidence also suggests a
protective role for this family of transcription factors in
atherogenesis [51,52]. A number of enzymes and regulatory
elements were also up-regulated by the anti-inflammatory agents.
The inducible cyclooxygenase isoform COX-2 is a pivotal and
rate-limiting enzyme in the inflammation-related generation of
Endogenous Resolution Pathways
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leukocytes and other inflammatory cells [21,22,35,53]. Suppressor
of cytokine signaling 3 is the main isoform of that family of
regulatory factors expressed in neutrophils and functions by
inhibiting JAK2 kinase activity [54–57]. DUSP 1 and 2 can
inactivate mitogen-activated protein kinases by dephosphorylating
phosphothreonine and phosphotyrosine residues. Phosphatases of
the DUSP family display specificity for different MAP kinases and
differ in tissue and sub-cellular distributions, although DUSP 2 is
expressed predominantly in hematopoietic tissues [58,59]. Finally,
IER2 attenuates the signaling activity of G proteins by binding to
GTP-bound G alpha subunits and by increasing the rate of
conversion from GTP to GDP [60]. Clearly, the up-regulation of
gene expression by adenosine and PGE2 occurs in a way that can
alter cellular programming at several levels.
Inhibition of key inflammatory factors is also likely pivotal for
mediating the potent anti-inflammatory activities of adenosine and
PGE2 in neutrophils. Indeed, activities of early-growth-response
transcription factors 2 and 3 are believed to have positive
involvement in differentiation, mitogenesis and angiogenesis [61],
while the phosphatase DUSP5 has been linked positively to
immunity through T cell development [62]. In the present study,
the only receptor to respond to anti-inflammatory agents (by down-
regulation of mRNA) was CD83, which is considered a marker of
mature dendritic cells and thought to be involved in the regulation
of T- and B-lymphocyte maturation. Although its expression on
neutrophils is known, its role is currently unknown [63,64]. As we
reported earlier, TNF-a expression is diminished by adenosine and
may well be one of the key targets of this autacoid. Indeed, TNF-a is
a pivotal pro-inflammatory cytokine involved in a number of
inflammatory and autoimmune diseases, diabetes and cancer
[65,66]. Similarly, MIP-1a is another important cytokine involved
in the acute inflammatory state and in the recruitment and
activation of neutrophils [67–69]. Endothelin 1 is a potent
vasoconstrictor that has been linked to graft rejection and to
inflammatory events including pain, fever, cell migration and
rheumatoid arthritis. It stimulates several mechanisms on neutro-
phils, including adhesion and migration [70–74].
Genes that were found to be affected by A2AR engagement,
PGE2 or pharmacological elevation of the intracellular cyclic AMP
concentration together provide a first picture of the overall impact
these signals have on gene expression. Furthermore, single anti-
inflammatory signals affected the expression of the same group of
genes, supporting the hypothesis that these genes play a role in the
coordination of a cellular response, this role being to limit cell
activation. It is therefore possible that the expression profile
observed in neutrophils will find similarities in other cell types and
tissues, and engage a resolution response. The current picture is
still partial; indeed, a number of affected sequences either code for
proteins not yet characterized or are altogether not translated.
Also, further studies will be necessary to confirm their involvement
in resolving inflammation. Nonetheless, genes identified in the
present study are likely to provide a better understanding of anti-
inflammatory signaling.
In summary, we have identified a series of genes for which
expression is altered by major anti-inflammatory signals. All of
theses signals affected the gene expression profile in remarkably
similar fashion. Characterization of these signaling pathways will
improve our understanding of the capacity of tissues to terminate
inflammation and may lead to the identification of better
therapeutic targets for the treatment of inflammatory diseases
associated with unrepressed neutrophil activation.
Materials and Methods
Materials
Anti-inflammatory agents. Compound CGS 21680 (2-[p-(2-
carboxyethyl) phenethylamino]-59-N-ethyl carboxamidoadenosine)
was from Research Biochemicals International (Natick, MA, USA).
Prostaglandin E2 (PGE2) was purchased from Cayman Chemicals
(Ann Arbor, MI, USA). Forskolin and RO 20-1724 were obtained
from EMD Chemicals (San Diego, CA, USA).
Inflammatory agonists. Lipopolysaccharide (LPS) from
Escherichia coli O111:B4 and formyl-methionyl-leucyl
phenylalanine (fMLP) were obtained from Sigma-Aldrich
(Oakville, ON, Canada). Recombinant human granulocyte-
macrophage colony-stimulating factor (GM-CSF), tumor necrosis
factor a (TNF-a) and interleukin 1b (IL-1b) were purchased from
PeproTech (Rocky Hill, NJ, USA).
Adenosine deaminase was purchased from Roche Applied
Science (Laval, QC, Canada).
Neutrophil isolation
Polymorphonuclear leukocytes were isolated as originally
described [75] with modifications [22]. Informed consent was
obtained in writing and all experiments involving human tissues
were approved by the Laval University Ethics Committee. Data
collection and analyses were performed anonymously. Briefly,
venous blood from healthy volunteers, collected on isocitrate
anticoagulant solution was centrifuged (2506g, 10 min) and the
resulting platelet-rich plasma was discarded. Leukocytes were
obtained following erythrocyte sedimentation in 2% Dextran T-
500 (Sigma-Aldrich). Granulocytes were then separated from
other leukocytes by centrifugation on a 10 ml cushion of
lymphocyte separation medium (Wisent, St-Bruno, QC, Canada).
Contaminating erythrocytes were removed by 15 seconds of
hypotonic lysis. Purified granulocytes (.95% neutrophils, ,5%
eosinophils) contained less than 0.1% monocytes, as determined
by esterase staining. Viability was greater than 98%, as
determined by tryptan blue dye exclusion. The whole cell isolation
procedure was carried out at room temperature under sterile
conditions.
Cell stimulations
Neutrophils were re-suspended at a concentration of 30610
6
cells/ml in Hank’s balanced salt solution at 37uC, containing 1%
fetal bovine serum, 10 mM HEPES pH 7.4, 1.6 mM Ca
2+ and no
Mg
2+. Adenosine deaminase (0.1 U/ml) was added to cell
suspensions 20 min prior to stimulation in order to prevent
accumulation of extracellular adenosine in cell suspensions, thus
minimizing the modulating effects of adenosine on neutrophil
activities [76]. Anti-inflammatory compounds dissolved in di-
Figure 2. Regulation of genes by anti-inflammatory agents in stimulated human neutrophils. Cells were pretreated with CGS 21680
(1 mM), PGE2 (10 mM) or a mixture of 10 mM RO-20-1724 and 50 mM forskolin, then stimulated as described in Materials and Methods for 30 min at
37uC, or for 2 h where indicated (
l). Top panels show genes that are up-regulated by the anti-inflammatory treatments and bottom ones show genes
that are down-regulated.Values are ratios of mRNA levels (treated cells/un-stimulated cells) as determined by real-time PCR, averaged6SEM for six
independent experiments performed under identical conditions with a different single donor of cells. *Significantly different from samples stimulated
in the absence of any anti-inflammatory agent.
doi:10.1371/journal.pone.0004902.g002
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stimulation with a mixture of LPS (100 ng/ml), GM-CSF
(1.4 nM), TNF-a (100 ng/ml), fMLP (100 nM) and IL-1b
(30 nM). Organic solvent concentration was identical in all
samples and did not exceed 0.1% (v/v). Stimulations were for
30 min at 37uC, unless indicated otherwise.
RNA isolation
Following stimulation, neutrophil total RNA was isolated using
Trizol (Invitrogen, Burlington, ON, Canada) according to the
manufacturer’s protocol, with modifications [22]. Briefly, a pellet
containing 30610
6 neutrophils was homogenized in 1 ml Trizol
and 200 ml of chloroform were added. After mixing, the sample
was centrifuged at 12,0006g for 15 min (4uC) and the upper
aqueous phase (450 ml) was transferred to a tube containing an
equal volume of isopropanol, mixed thoroughly using a vortex
device and centrifuged at 12,0006g for 10 min (4uC). The
supernatant was discarded and the precipitated RNA pellet was
washed twice using 500 ml of 75% ethanol and centrifuged at
12,0006g for 5 min (4uC). The final pellet was allowed to air-dry
for 5–10 min and was then re-suspended in RNAse-free water.
RNA was quantitated using a Qubit
TM Fluorometer (Invitrogen).
DNA microarrays
Equal quantities of total RNA obtained from neutrophils of five
donors were pooled together and purified on QIAGEN RNeasy
column (QIAGEN, Mississauga, ON, Canada). Ten ng of total
RNA were converted to cDNA using Superscripts reverse
transcriptase (Invitrogen) and T7-oligo-d(T)24 primers (Applied
Biosystems, Austin, TX, USA). Second-strand synthesis was
performed using T4 DNA polymerase and E. coli DNA ligase
and then blunt-ended by T4 polynucleotide kinase. cDNA was
purified by phenol-chloroform extraction using phase lock gels
(Brinkmann, Westbury, NY, USA), then transcribed in vitro for
16 h at 37uC by using the IVT Labelling Kit (Affymetrix, Santa
Clara, CA, USA) to produce biotinylated cRNA. Biotin-labelled
cRNA was isolated using the RNeasy Mini Kit column
(QIAGEN). Purified cRNA was fragmented to 30–200 nucleotide
lengths using a fragmentation buffer. The quality of total RNA,
cDNA synthesis, cRNA amplification and cRNA fragmentation
was monitored and confirmed by capillary electrophoresis
(Bioanalyzer 2100, Agilent Technologies, Santa Clara, CA,
USA). Fifteen mg of fragmented cRNA were hybridized for 16 h
at 45uC with constant rotation on a Human Genome U133 Plus
2.0 GeneChip Array (Affymetrix). After hybridization, gene chips
were processed with the Affymetrix GeneChip Fluidic Station 450
(protocol EukGE-WS2v5_450). Briefly, staining was made with
streptavidin-conjugated phycoerythrin (SAPE, Invitrogen) fol-
lowed by amplification with a biotinylated anti-streptavidin
antibody (Vector Laboratories, Burlingame, CA, USA) and by a
second round of SAPE. Chips were scanned using a GeneChip
Scanner 3000 G7 (Affymetrix) enabled for High-Resolution
Scanning. Images were extracted with the GeneChip Operating
Software (Affymetrix GCOS v1.4). Quality control of microarray
chips was performed using the AffyQCReport software [77]. All
Microarray data is conform to the MIAME guidelines; unsuper-
vised, raw data was deposited in the GEO database (geo@ncbi.
nlm.nih.gov), submission number: GSE14465.
Interpretation of microarray results
Sequences with a level of expression of 200 and over were
considered to be positively expressed. A sequence was considered
differentially expressed when the ratio of expression level between
experimental conditions was $2( $two-fold increase) or #0.5 (two-
fold decrease). Gene identification and expression levels were
analyzed using the Gene Set Analysis Toolkit, developed and
maintained by members of the Department of Biomedical Informat-
ics and the Department of Biostatistics of the Vanderbilt University
Medical Center (http://bioinfo.vanderbilt.edu/webgestalt) [34].
Real-Time PCR
First-strand cDNA synthesis was performed using 1 mg of total
RNA with Superscript II (Invitrogen) following the manufacturer’s
instructions, using 500 ng of random hexamers. Real-time PCR
was performed as described elsewhere [78]. Briefly, cDNA
amplification was carried out in a Rotor-Gene 3000 operated
with Rotor-Gene software version 6.0.19 (Corbett Research,
Mortlake, NSW Australia) using 35 cycles of 95uC, 58uC and 72uC
for 20 seconds each. Each sample consisted of 40 ng of cDNA,
2 mlo f1 0 6buffer (100 mM Tris, 500 mM KCl, 30 mM MgCl2,
1.5% Triton X-100), 0.5 mM dNTP, 500 nM of primers, 0.1 unit
of rTaq DNA polymerase (GE Healthcare, Piscataway, NJ, USA)
and SYBR Green I dye (Invitrogen; 1:30,000 dilution) in a
reaction volume of 20 mL. Reaction specificity was ascertained by
performing the MeltH procedure (58–99uC, 1uC/5 s) at the end of
the amplification protocol, according to the manufacturer’s
instructions. For each gene of interest, specific primers were
designed as described previously [78]. Briefly, primers were
selected systematically within the coding region, with a theoretical
melting point of 58uC, GC content of 50% (610%) and length of
18–24 bp, for an average product length of 200 bp. Primers thus
designed were all tested with gradient PCR prior to their use in
real-time PCR and are listed in Supplementary Table S5.
Experimental design
The following experimental treatment conditions were exam-
ined: Unstimulated control cells; stimulated cells; cells stimulated
in the presence of either CGS 21680, PGE2, or forskolin & RO 20-
1724; cells stimulated in the simultaneous presence of CGS 21680,
PGE2 and forskolin & RO 20-1724; unstimulated cells in the
simultaneous presence of CGS 21680, PGE2 and forskolin & RO
20-1724.
DNA microarray experiments were repeated twice, each using
RNA pooled from neutrophils of five donors. Real-time PCR
experiments were repeated six times for cell stimulation in the
absence of anti-inflammatory agents and for stimulation in the
presence of CGS 21680, PGE2, or forskolin plus RO 20-1724
(each repetition with neutrophils from one of six donors) and
Figure 3. Impact of a combination of anti-inflammatory agents on gene expression in stimulated human neutrophils. Cells were
pretreated with CGS 21680 (1 mM), PGE2 (10 mM), RO-20-1724 (10 mM) and forskolin (50 mM) simultaneously, then stimulated as described in Materials
and Methods for 30 min at 37uC, or for 2 h where indicated (
l). Top panels show genes that are up-regulated by the anti-inflammatory treatments and
bottom ones show genes that are down-regulated. The dotted line indicates the level of expression observed in un-stimulated cells (=1). Values are
ratios of mRNA levels (treated cells/un-stimulated cells) as determined by real-time PCR, averaged6SEM for three independent experiments
performed under identical conditions with a different single donor of cells. *Significantly higher than in un-stimulated samples. **Significantly higher
than in un-stimulated samples and in samples stimulated in the absence of anti-inflammatory agent. ‘‘#’’ Significantly higher than in un-stimulated
samples but significantly lower than in samples stimulated in the absence of anti-inflammatory agent.
doi:10.1371/journal.pone.0004902.g003
Endogenous Resolution Pathways
PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4902Endogenous Resolution Pathways
PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4902repeated three times for the time-course study of CGS 21680 (each
repetition with neutrophils from one of three donors),
Statistical analysis
Where applicable, statistical analysis was performed using the
Student’s non-paired t-test (two-tailed) and differences were
considered significant (marked by an asterisk) when p,0.05.
Supporting Information
Table S1 Gene-chip-based identification of differentially regu-
lated genes in stimulated human neutrophils. Genes are listed in
decreasing order of the mRNA expression ratio (stimulated/un-
stimulated cells). Cells were stimulated as described in Materials
and Methods for 30 min at 37 degrees C. RNA from five donors
was pooled for analysis. Results are from one experiment.
Found at: doi:10.1371/journal.pone.0004902.s001 (0.09 MB
DOC)
Table S2 Inflammatory genes that are differentially- expressed
in stimulated human neutrophils (Genechip results). Cells were
stimulated as described in Materials and Methods for 30 min at
37 degree C. RNA from five donors was pooled for analysis.
Genes from Supplementary Table S1 were selected for their
potential involvement in inflammatory processes, and based on
differential regulation in stimulated human neutrophils, as
revealed by genechip analysis. Genes are listed in decreasing
order of the mRNA expression ratio (stimulated/un-stimulated
cells). Results are from one experiment.
Found at: doi:10.1371/journal.pone.0004902.s002 (0.15 MB
XLS)
Table S3 Differentially-expressed genes in stimulated human
neutrophils treated with anti-inflammatory agents (Genechip
results) Cells were pretreated with CGS 21680 (1 uM), PGE2
(10 uM) or a mixture of 10 uM RO-20-1724 and 50 uM forskolin,
then stimulated for 30 min with the inflammatory cocktail for
30 min at 37 degree C, as described in Materials and Methods.
RNA from five donors was pooled for analysis. Genes are listed in
decreasing order of the mRNA expression ratio (stimulated/un-
stimulated cells). Results are from one experiment.
Found at: doi:10.1371/journal.pone.0004902.s003 (0.16 MB
XLS)
Table S4 List of genes, their associated proteins and protein
functions, differentially regulated in stimulated human neutrophils
and influenced by anti-inflammatory agents, as confirmed by real-
time PCR.
Found at: doi:10.1371/journal.pone.0004902.s004 (0.03 MB
XLS)
Table S5 List of PCR primers.
Found at: doi:10.1371/journal.pone.0004902.s005 (0.16 MB
XLS)
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